Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil.
Atherosclerosis. 2017 Aug;263:257-262. doi: 10.1016/j.atherosclerosis.2017.06.917. Epub 2017 Jun 22.
BACKGROUND AND AIMS: There is controversy on the accuracy of different diagnostic criteria for familial hypercholesterolemia (FH). The aim of this study is to assess the performance of different clinical criteria used to identify individuals for FH genetic cascade screening in Brazil. METHODS: All index cases (IC) registered in the Hipercol Brasil program between 2011 and 2016 were analyzed. Inclusion criteria were age ≥18 years and elevated LDL-cholesterol (LDL-C) levels, with a conclusive result in the genetic test, whether positive or negative. Initially, we tested the multivariable association between clinical and laboratory markers and the presence of an FH causing mutation. Then, we analyzed sensitivity, specificity, positive and negative predictive values for the LDL-C quartile distribution, LDL-C as a continuous variable, as well as the performance measures for the Dutch Lipid Clinic Network (DLCN) score to identify a mutation. RESULTS: Overall, 753 ICs were included and an FH causing mutation was found in 34% (n = 257) of the subjects. After multivariable analysis, LDL-C as a continuous variable, tendon xanthomas and corneal arcus were independently associated with the presence of FH mutations. LDL-C values ≥ 230 mg/dL (5.9 mmol/L) had the best tradeoff between sensitivity and specificity to diagnose a mutation. The DLCN score presented a better performance than LDL-C to identify a mutation, area under the ROC curve were 0.744 (95% CI: 0.704-0.784) and 0.730 (95% CI: 0.687-0.774), respectively, p=0.014. CONCLUSIONS: In our population, LDL ≥230 mg/dL is a feasible criterion to indicate ICs to genetic testing.
背景和目的:不同的家族性高胆固醇血症(FH)诊断标准的准确性存在争议。本研究旨在评估巴西用于 FH 遗传级联筛查的不同临床标准的性能。
方法:分析了 2011 年至 2016 年期间在 Hipercol Brasil 计划中登记的所有索引病例(IC)。纳入标准为年龄≥18 岁和 LDL-胆固醇(LDL-C)水平升高,遗传检测结果有结论,无论阳性或阴性。最初,我们测试了临床和实验室标志物与 FH 致病突变之间的多变量关联。然后,我们分析了 LDL-C 四分位分布、作为连续变量的 LDL-C 以及荷兰脂质诊所网络(DLCN)评分对识别突变的敏感性、特异性、阳性和阴性预测值。
结果:共纳入 753 例 IC,其中 34%(n=257)的患者存在 FH 致病突变。经过多变量分析,连续变量的 LDL-C、腱黄瘤和角膜弓与 FH 突变的存在独立相关。LDL-C 值≥230mg/dL(5.9mmol/L)在诊断突变的敏感性和特异性之间具有最佳的权衡。DLCN 评分在识别突变方面优于 LDL-C,ROC 曲线下面积分别为 0.744(95%CI:0.704-0.784)和 0.730(95%CI:0.687-0.774),p=0.014。
结论:在我们的人群中,LDL-C≥230mg/dL 是指示 IC 进行基因检测的可行标准。
Atheroscler Plus. 2022-6-28